Conference Coverage

Experience – not evidence – is best guide in keloid treatment


 

AT SDEF LAS VEGAS DERMATOLOGY SEMINAR

– The first written mention of keloids in history came about 4,500 years ago. But there is still so much more to be learned about keloids, according to dermatologist Hilary E. Baldwin, MD.

Yes, there is more information about who gets keloids and where they appear on the body. “What we do not know is everything else,” Dr. Baldwin said at Skin Disease Education Foundation’s annual Las Vegas Dermatology Seminar. “We don’t even know which treatments work. Not a single treatment has any evidence basis behind it. It’s all fly-by-night, seat-of-your-pants, based on your knowledge and that of those who treat keloids frequently.”

While keloids are caused by trauma to the skin, even by something like acne, she pointed out that trauma alone is not the entire explanation. Cases show an unknown factor serves as a contributing factor, she said.

There’s no gender disparity in keloids, she said, and they’re more likely to occur after puberty than before. Family history isn’t helpful.

Also, while darker skin produces keloids more easily and consistently than other skin types, these keloids aren’t the hardest to treat, said Dr. Baldwin, medical director of the Acne Treatment and Research Center in Morristown, N.J. “From my personal experience – but not from data or papers – keloids are the most difficult to treat and recur the most when you see them in a Caucasian patient.”

Patients want the keloids to disappear forever along with any evidence that they ever existed. “Virtually every patient says ‘I want this cut off, I want it gone,’” Dr. Baldwin said. “And they want it gone yesterday. Few understand this is a long process. I tell them we’ll become extraordinarily good friends over the next 6-12 months while we get rid of this thing.” Moreover, it’s not possible to eliminate keloids without leaving a sign behind. “Most want it eradicated with normal skin,” but the skin beneath a keloid “will never look normal,” she observed.

Pages

Recommended Reading

Most dermatologic drugs safe for breastfeeding mothers
MDedge Dermatology
Anti-RNPC3 antibody positive status linked to GI dysmotility in systemic sclerosis
MDedge Dermatology
Consider different etiologies in patients with vaginal pruritus
MDedge Dermatology
Review finds some therapies show promise in managing prurigo nodularis
MDedge Dermatology
November 2018
MDedge Dermatology
SLE low-disease definition receives prospective validation
MDedge Dermatology
Serlopitant quells prurigo nodularis in phase 2 study
MDedge Dermatology
Leflunomide-hydroxychloroquine combo shows promise in primary Sjögren’s pilot study
MDedge Dermatology
Delusional infestation: not so rare
MDedge Dermatology
Investigational agent VT-1161 looks promising for onychomycosis
MDedge Dermatology